International Isotopes Inc. Reports 12% Revenue Growth in Q1 2025

International Isotopes Inc. (INIS) reported its financial results for the first quarter of 2025, revealing a total revenue of $3.24 million, a 12% increase from $2.90 million in the same period of 2024. The growth in revenue was primarily driven by a significant rise in the Nuclear Medicine Standards segment, which saw sales increase by approximately 73% year-over-year. However, this was partially offset by declines in the Theranostics Products and Cobalt Products segments, which experienced decreases of 6% and 69%, respectively. The company's gross profit for the quarter was $2.03 million, up from $1.87 million in the prior year, reflecting a gross profit margin of 63%.

Operating expenses for the quarter decreased slightly to $2.10 million from $2.13 million in the previous year, primarily due to reduced general and administrative costs. The company reported a net loss of $112,694, an improvement from the net loss of $154,051 in the first quarter of 2024. This reduction in losses was attributed to increased sales in the Nuclear Medicine Standards segment and improved gross profit margins, despite challenges in other product lines.

In terms of operational developments, International Isotopes has been focusing on its core business segments, particularly the Theranostics Products, Cobalt Products, and Nuclear Medicine Standards. The company is also in the process of launching its Medical Device segment, which includes products acquired from AMICI, Inc. in 2023. The company has entered into a strategic development and distribution agreement with Alpha Nuclide Inc. to manufacture and distribute its Theranostics Products in China, marking a significant geographic expansion.

As of March 31, 2025, the company reported total assets of $17.57 million, an increase from $17.16 million at the end of 2024. Cash and cash equivalents decreased to $1.65 million from $1.95 million, while accounts receivable rose to $1.69 million, indicating improved sales activity. The company’s liabilities increased to $13.23 million, up from $12.81 million, largely due to an increase in current liabilities, including unearned revenue, which rose to $773,423 from $513,317.

Looking ahead, International Isotopes expects that its current cash balance, along with cash generated from operations and potential equity or debt financing, will be sufficient to fund its operations for the next twelve months. The company is also anticipating the completion of the sale of its Fluorine Products segment and the planned Uranium De-Conversion Facility, which is expected to generate approximately $12.5 million, contingent upon regulatory approvals. The management remains cautious about future liquidity and capital funding requirements, emphasizing the need for ongoing evaluation of market conditions and operational performance.